INVESTABOT
Equity Research
XNYS · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
Charles River Laboratories International (CRL) had 1 Form 144 pre-sale notice filed on 2026-08-10. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed…
Charles River Laboratories International (CRL) had 1 Form 144 pre-sale notice filed on 2026-08-05. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed…
Charles River Laboratories International (CRL) had 1 Form 144 pre-sale notice filed on 2026-08-25. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed…
Charles River Laboratories International (CRL) had 1 Form 144 pre-sale notice filed on 2026-08-18. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed…
Charles River Laboratories International (CRL) had 1 Form 144 pre-sale notice filed on 2026-08-19. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed…
Charles River Laboratories International (CRL) had 2 Form 144 pre-sale notices filed on 2026-08-11. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed…
Charles River Laboratories International (CRL) had 2 Form 144 pre-sale notices filed on 2026-08-06. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed…
Charles River Laboratories International (CRL) had 1 Form 144 pre-sale notice filed on 2026-06-29. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed…
TL;DR: Charles River Laboratories reported Q1 2026 revenue of $995.8 million, up 1.2% from $984.2 million a year ago, while non-GAAP EPS came in at $2.06 versus $2.34 in Q1 2025 — a 12% decline. The GAAP headline looks…
open-market Form 4 only - grants, exercises, tax withholding excluded
0 buyers - 6 unique sellers · Institutional activity: not available - insufficient comparable institutions for the latest complete quarter.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| August 25, 2026 | Foster James C | — | OPTION_EXERCISE | 21,132 | $194 | ~$4.1M |
| August 25, 2026 | Foster James C | — | OPTION_EXERCISE | 12,429 | $208 | ~$2.6M |
| August 25, 2026 | Foster James C | — | SELL | -33,561 | $300 | ~$10.1M |
| August 25, 2026 | Foster James C | — | OPTION_EXERCISE | -21,132 | — | — |
| August 25, 2026 | Foster James C | — | OPTION_EXERCISE | -12,429 | — | — |
| August 19, 2026 | Girshick Birgit | Chief Executive Officer | GIFT | -528 | — | — |
| August 19, 2026 | Parisotto Shannon M | CEVP, Disc & Safety Assessment | OPTION_EXERCISE | 2,039 | $194 | ~$0.4M |
| August 19, 2026 | Parisotto Shannon M | CEVP, Disc & Safety Assessment | SELL | -2,039 | $294 | ~$0.6M |
| August 19, 2026 | Parisotto Shannon M | CEVP, Disc & Safety Assessment | OPTION_EXERCISE | -2,039 | — | — |
| August 18, 2026 | Andrews Nancy C | — | OPTION_EXERCISE | 573 | $164 | ~$94K |
| August 18, 2026 | Andrews Nancy C | — | SELL | -573 | $285 | ~$0.2M |
| August 18, 2026 | Andrews Nancy C | — | OPTION_EXERCISE | -573 | — | — |
| August 11, 2026 | Girshick Birgit | Chief Executive Officer | OPTION_EXERCISE | 6,500 | $180 | ~$1.2M |
| August 11, 2026 | Girshick Birgit | Chief Executive Officer | SELL | -6,500 | $280 | ~$1.8M |
| August 11, 2026 | Girshick Birgit | Chief Executive Officer | OPTION_EXERCISE | -6,500 | — | — |
| August 11, 2026 | Parisotto Shannon M | CEVP, Disc & Safety Assessment | OPTION_EXERCISE | 3,714 | $180 | ~$0.7M |
| August 11, 2026 | Parisotto Shannon M | CEVP, Disc & Safety Assessment | SELL | -3,714 | $280 | ~$1.0M |
| August 11, 2026 | Parisotto Shannon M | CEVP, Disc & Safety Assessment | OPTION_EXERCISE | -3,714 | — | — |
| August 10, 2026 | LaPlume Joseph W | EVP, Corp Strategy & Develop | GIFT | -257 | — | — |
| August 10, 2026 | Foster James C | — | OPTION_EXERCISE | 28,733 | $180 | ~$5.2M |
| Date | Filer | Relationship | Est. shares | Filing |
|---|---|---|---|---|
| August 25, 2026 | Foster James C | — | 33,561 | SEC |
| August 19, 2026 | Parisotto Shannon M | — | 2,039 | SEC |
| August 18, 2026 | Nancy C Andrews | — | 573 | SEC |
| August 11, 2026 | Parisotto Shannon M | — | 3,714 | SEC |
| August 11, 2026 | Girshick Birgit | — | 6,500 | SEC |
| August 10, 2026 | Foster James C | — | 28,733 | SEC |
| August 6, 2026 | — | — | — | SEC |
| August 6, 2026 | — | — | — | SEC |
| August 5, 2026 | Parisotto Shannon M | — | 5,046 | SEC |
| June 29, 2026 | Foster James C | — | 75,000 | SEC |